ABIO Bullish Divergence.Hello, What is ABIO? ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF. This chart was not easy to do because I got stuck on its all-time high, check the snapshot below. Anyways, we do have a divergence at play but it seems to be in a little correction and I suspect it is going to test support before going up. If you look at the chart I have located the possible bounce area marked with a dotted horizontal ray. How high can it go is the question and I leave that to you the reader to decide. Be sure to comment, follow, like, and check out my profile for more trade ideas! Good Luck, Cheers! Longby keifer12
AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19ARCA BIOPHARMA ANNOUNCES AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19 ASSOCIATED COAGULOPATHY arcabio.com The Westminster, Colorado-based company said it plans to evaluate AB201, a selective inhibitor of tissue factor, as a potential treatment for COVID-19-associated coagulopathy and the related inflammatory response. Coagulopathy is among the most serious adverse effects seen in COVID-19 patients, according to Arca. The company said its AB201 has been previously tested through Phase 2 trials in more than 700 patients for other indications and has generated substantial safety data. A Phase 2b/3 protocol is being developed in collaboration with the Colorado Prevention Center, the research wing of the University of Colorado, for hospitalized COVID-19 patients with elevated D-dimer levels, the company said. www.benzinga.com www.globenewswire.com by AlenCiken4
What if this is bullish price action?Maybe it's too early to tell but I like itLongby dobisaUpdated 2
ABIO GannUpon Request backtest only. I don't trade usually trade penny craps because most of them are a pump and dump scheme. Might take down this "unethical investment" sooner or later.Shortby UnknownUnicorn10206213
$ABIO Breakout in ARCA BIO-PHARM 80% UPSIDE POTENTIAL Be on the watch-out for massive continuation today after great results yesterday. Already up 19% premarket. RESULTS TRANSCRIPT “In the first part of this year, we continued to make progress on our lead development program Gencaro, achieving an agreement with the FDA on our Special Protocol Assessment for the PRECISION-AF Phase 3 clinical trial evaluating Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and Chief Executive Officer. “Importantly, the GENETIC-AF Phase 2B clinical trial results, which are guiding our Phase 3 development, were accepted and published in JACC: Heart Failure.” Company Description ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indicationsLongby DEXWireNews7
ARCA Biopharma Announces FDA Agreement for a Single Phase 3today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 clinical trial, PRECISION-AF, to assess the safety and efficacy of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF). finance.yahoo.com by AlenCiken0
ABIO Where From HereBiggest gapper today #ABIO $ABIO, fell right away at market open. Looks to be setting up some possible support, ill watch it tomorrow and the next few days to see if we can break back above the median. You can visit my youtube and watch my full video recap, link in the description!by TradeWithTyler1
What I like about ABIO as a swing playWhat I like about ABIO as a swing play: 1. All moving avgs in alignment 2. Even with today's bearish candle, we still have a hook 3. We are still possibly coming out of oversold 4. The MACD is about to give a buy signal 5. They had positive news Feb 27 6. Traders love filling the gap from Feb 23 7. Needs to keep having higher highs and higher lows. 8. Needs to stay above RSI 30 9. Needs a significant hook continuation on 8ma. 10. Low short interest 11. At best a medium risk swing play. If you like my ideas, consider subscribing to my free overnight hold alerts discord.gg Longby Round_Table_Trade_Team_LLC4
ONE OF THE BEST STOCKS TO RISK 1000$I WANT TO PRESENT YOU ONE OF THE BEST STOCKS I FOUND WITH SUPER POTENTIAL TO BECAME BIGGEST WINNER .I THINK THIS COMPANY WILL PERFORMING BETTER AND BETTER FOR THE FUTURE.ITS RISKY BUT FOR ONLY 1000 $ YOU COULD BECOME VERY RICH IF THE PRICE GO TO OLD LEVELS.WITH 1000$ NOW YOU COULD BUY 1000 SHARES AND I AM OPTIMISTIC ABOUT 2-3 YEARS AFTER THAT THE PRICE WILL BE 50$ FOR SHARE OR MORE.LIKE PETER LYNCH SAID : ITS VERY HARD ONE COMPANY WITH NO DEBT TO FAIL - I LIKE THAT AND THIS COMPANY HAS NO DEBT,CURRENT RATIO IS BIIIG - THERE IS NO WAY TO GO UNDER AND EVEN IF IT GO - DESERVE TO RISK 1000$ - WITH MARGIN IT WILL COST ME 300$ - ITS NOTHING COMPARE TO POSSIBLE RETURN.P/B RATIO IS NEAR 0.50 - NOW IS THE TIME TO BUY AND THEN SIT AND WAIT TO HIT THE SKY HAHHA - SERIOSLY THE STOCK WAS 500$ PER SHARE NOT LONG AGO,IT IS POSSIBLE TO RETURN AND THIS MAY BE VERY SOON - BIOTECH IS VERY GOOD BIUSNESS - THE COMPANY HAS GOOD ASSTES EVEN IF IT FAIL WITH P/B RATIO NEAR 0.5 AND NO DEBT I AM SURE SOME OF THE BIGGEST INVESTORS WILL MAKE A MOVE OR IF IT FAIL THERE IS GOOD ASSTES WHICH WILL BE SALING FAST - ITS TECHNOLOGY AFTER ALL AND MACHINES ARE EXPENSIVE WITH NO DEBT SHAREHOLDERS WILL TAKE SOMETHINGLongby dimokirlov0
Chart UpdateStrong bullish follow through after breaking above trend line. May test $2.54 soon.Longby StockSprinter0
Upside breakoutABIO is at 52week low and ready for a Upside breakout! Very cheap a lot of room for some good profit! Longby dias7240